Detalhe da pesquisa
1.
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Blood
; 141(11): 1265-1276, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265087
2.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10399): 373-385, 2023 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37311468
3.
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Blood
; 137(6): 751-762, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32929488
4.
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
N Engl J Med
; 381(18): 1728-1740, 2019 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31665578
5.
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment.
Hematol Oncol
; 40(4): 734-742, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35618655
6.
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents.
Eur J Haematol
; 108(6): 449-459, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35156731
7.
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement.
Acta Haematol
; 144(6): 688-692, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34130278
8.
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia.
Eur J Haematol
; 105(1): 47-55, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32145118
9.
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.
Cancer
; 125(5): 712-725, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30480765
10.
Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Haematologica
; 104(2): 312-318, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30190342
11.
Bad Is Stronger Than Good for Stigmatized, but Not Admired Outgroups: Meta-Analytical Tests of Intergroup Valence Asymmetry in Individual-to-Group Generalization Experiments.
Pers Soc Psychol Rev
; 23(1): 3-47, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29473444
12.
Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature.
Mycoses
; 62(12): 1100-1107, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31365161
13.
Mediating Effects of the 'eCoFit' Physical Activity Intervention for Adults at Risk of, or Diagnosed with, Type 2 Diabetes.
Int J Behav Med
; 26(5): 512-521, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31270732
14.
Acute Myeloid Leukemia Mutations: Therapeutic Implications.
Int J Mol Sci
; 20(11)2019 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31163594
15.
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.
BMC Cancer
; 18(1): 1117, 2018 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442119
16.
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Am J Hematol
; 98(8): E204-E208, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37222267
17.
Increased angiogenesis seems to correlate with inferior overall survival in myeloid sarcoma patients.
Pol J Pathol
; 69(3): 254-265, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30509052
18.
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
BMC Cancer
; 17(1): 523, 2017 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28779753
19.
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.
Hematol Oncol
; 39(4): 580-583, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33963566
20.
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
Am J Hematol
; 90(6): 515-23, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25753065